The Claim
In adults with obesity and prediabetes, the combination of bimagrumab and semaglutide results in 100% reversion to normoglycemia (HbA1c <5.7%) by week 72, while semaglutide alone results in 96% reversion and placebo results in 53% reversion.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity and prediabetes, taking both bimagrumab and semaglutide for 72 weeks leads to complete normalization of blood sugar levels in 100% of participants, compared to 96% with semaglutide alone and 53% with a placebo.
See the scientific wording
In adults with obesity and prediabetes, the combination of bimagrumab and semaglutide achieves 100% reversion to normoglycemia (HbA1c <5.7%) by week 72, compared to 96% with semaglutide alone and 53% with placebo, indicating additive effects on glycemic control.
Blocking a signal that limits muscle growth and fat breakdown increases fat burning and keeps muscle intact, while reducing hunger causes the body to use stored fat for energy. This combination lowers fat around organs and in the liver, which allows the pancreas to produce insulin properly and the body to use sugar normally.
What the research says
1 studyIn people with obesity and prediabetes, taking both drugs together brought everyone’s blood sugar back to normal within 72 weeks — better than either drug alone or no treatment, according to the study.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.